What is Techcyte?
Techcyte is at the forefront of developing sophisticated AI-driven digital pathology solutions tailored for laboratories. The company's advanced software platforms leverage machine learning and automation to analyze medical samples, including blood, tissue, and cytology slides. By enhancing diagnostic accuracy and operational efficiency, Techcyte supports critical workflows in clinical, veterinary, and environmental testing, positioning itself as a key innovator in modern laboratory systems.
How much funding has Techcyte raised?
Techcyte has raised a total of $40.5M across 4 funding rounds:
Private Equity
$4.3M
Debt
$150K
Unspecified
$21M
Unspecified
$15M
Private Equity (2018): $4.3M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Unspecified (2021): $21M supported by ARUP Laboratories and Zoetis
Unspecified (2026): $15M featuring Van Tuyl Companies
Key Investors in Techcyte
ARUP Laboratories
ARUP Laboratories, founded in 1984 and located in Salt Lake City, Utah, is a national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology.
Zoetis
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
What's next for Techcyte?
The recent strategic investment signals a new phase of growth and development for Techcyte. With a focus on scaling its AI-powered diagnostic tools, the company is poised to further penetrate the healthcare technology market. Future endeavors will likely involve expanding its platform capabilities, forging new partnerships, and enhancing its market reach to support a broader range of laboratory applications, solidifying its position as a leader in digital pathology.
See full Techcyte company page
